Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Ascendis Pharma (Nasdaq: ASND) will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 11:10 a.m. ET.
A live webcast and a replay available for 30 days will be accessible via the companys Investors & News website at investors.ascendispharma.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers EXEL, IONS, SMMT, BBIO and BMRN all showed positive moves (e.g., SMMT up 6.28%), but momentum scanners did not flag a coordinated sector move, suggesting ASND’s action was more stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings results | Positive | -1.5% | Reported strong 2025 revenue growth with Q4 profitability but full-year net loss. |
| Feb 04 | Earnings date set | Neutral | -1.1% | Announced timing and webcast details for full-year 2025 results and update. |
| Jan 09 | Strategic roadmap | Positive | +2.8% | Outlined 2026 roadmap, preliminary 2025 metrics and a $120M share repurchase plan. |
| Jan 08 | Clinical trial data | Positive | -2.8% | Phase 2 COACH trial showed durable growth benefits in children with achondroplasia. |
| Jan 05 | Conference participation | Neutral | -0.1% | Announced participation and webcast access for J.P. Morgan Healthcare Conference. |
Positive clinical and earnings updates have sometimes seen negative next-day reactions, while strategic roadmap news drew a positive response.
Over recent months Ascendis has reported strong commercial growth and pipeline progress. Q4 and full-year 2025 results showed rising revenue but a continued net loss, with TransCon CNP under FDA Priority Review and a PDUFA date of Feb 28, 2026. The company outlined a 2026 roadmap, including TransCon PTH, TransCon CNP and TransCon hGH programs, and participated in major conferences like the 44th Annual J.P. Morgan Healthcare Conference. Today’s TD Cowen conference appearance fits this pattern of ongoing investor outreach and visibility events.
Market Pulse Summary
This announcement highlights Ascendis Pharma’s participation in the TD Cowen 46th Annual Health Care Conference, with a webcast at 11:10 a.m. ET and replay access for 30 days. It continues a series of investor‑facing events following recent earnings, roadmap updates, and significant regulatory milestones. Investors may focus on any incremental commentary on commercial performance, TransCon pipeline progress, and capital allocation, especially in light of prior disclosures about revenue growth alongside ongoing net losses and strategic investments.
AI-generated analysis. Not financial advice.
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (ii) Ascendis’ ability to apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, and TransCon are trademarks owned by the Ascendis Pharma group. © March 2026 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Chad Fugere | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | media@ascendispharma.com |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com | |
FAQ
When will Ascendis Pharma (ASND) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch the Ascendis Pharma (ASND) fireside chat webcast on March 2, 2026?
Will Ascendis Pharma (ASND) provide a replay of the TD Cowen conference presentation?
What time is Ascendis Pharma's (ASND) virtual fireside chat in Pacific Time on March 2, 2026?
